|
Jan 16
|
Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
|
|
Jan 10
|
Adagene Inc.'s (NASDAQ:ADAG) market cap surged US$34m last week, retail investors who have a lot riding on the company were rewarded
|
|
Nov 3
|
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
|
|
Aug 31
|
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
|
|
May 25
|
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?
|